Safety and Immunogenicity of AdCh63 ME-TRAP and MVA ME-TRAP Vaccines in Malaria Endemic Areas

Inclusion Criteria: * Consenting adult males aged 18-50 years in good health. * Will remain resident in the study area for the study duration Exclusion Criteria: * Clinically significant history of the following conditions; skin disorder (eczema, etc.), allergy, symptomatic immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness. * History of splenectomy * Haemoglobin less than 9.0 g/dl * Clinically significant abnormalities of laboratory screening tests (full blood count, ALT, creatinine levels, urine dipstick examination for blood and protein). * Blood transfusion within one month of the beginning of the study * History of vaccination with previous experimental malaria vaccines * Administration of any other vaccine or immunoglobulin within two weeks before vaccination. * Current participation in another clinical trial, or within 12 weeks of this study * Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial. * Likelihood of travel away from the study area * HIV positive. * History of contact dermatitis (due to the use of a potentially irritant disinfectant that may be present in trace amounts in the AdCh63 ME-TRAP vaccine, see the investigators brochure for details, attached)